Lisuride
| Lisuride | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 338.40 g/mol [1] |
| Solubility | 1.40e-01 g/L [1] |
| Predicted LogP | 2.7 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C20H26N4O |
| IUPAC name | 3-[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea |
| SMILES | CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C |
| InChI | InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1 |
| InChIKey | BKRGVLQUQGGVSM-KBXCAEBGSA-N |
| CAS number | 18016-80-3 |
| UNII | E0QN3D755O |
| PubChem CID | 28864 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 2 hours |
| Metabolism | Hepatic |
| Excretion | Renal and biliary in equal amounts |
| Routes of administration | Oral, Investigational: Subcutaneous implant, transdermal patch |
Lisuride (also known as Lysuride, Lisurida, Lisuridum, Dopergin, N'-((8α)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea, Methylergol Carbamide, Lysurid, Urea, N'-((8α)-9,10-didehydro-6-methylergolin-8-yl)-N,N-diethyl-, Mesylate, Lisuride or Revanil 200) is a substance of the ergoline and amphetamine class.
Chemistry
Stereochemistry []
Lisuride is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Lisuride matches Lipinski's rule of five.Pharmacology
ATC Classification
- genito urinary system and sex hormones (G)
- other gynecologicals (G02)
- other gynecologicals (G02C)
- prolactine inhibitors (G02CB)
- lisuride (G02CB02)
- nervous system (N)
- analgesics (N02)
- antimigraine preparations (N02C)
- ergot alkaloids (N02CA)
- lisuride (N02CA07)
MeSH Classification
Mechanism of action []
Lisuride is an anti-Parkinson drug chemically related to the dopaminergic ergoline Parkinson's drugs. Lisuride binds to the 5-HT(1A) and 5-HT(2A/2C) receptors. It is also thought to bind to the dopamine receptor and to act as a dopamine agonist. Evidence has also emerged that Lisuride also binds to the Histamine H1 receptor. [1]
Interactions []
Medical side effects []
61 side effects listed on drug labels in SIDER 4.1 (lisuride).
- Decreased appetite
- Anxiety
- Mental disorder
- Infection
- Confusional state
- Feeling abnormal
- Cough
- Dehydration
- Dizziness
- Dyspnoea
- Erythromelalgia
- Asthenia
- Fatigue
- Gastrointestinal disorder
- Hallucination
- Headache
- Cardiac disorder
- Cardiac valve disease
- Hyperprolactinaemia
- Orthostatic hypotension
- Immune system disorder
- Libido increased
- Disturbance in sexual arousal
- Mediastinal disorder
- Myoclonus
- Nervous system disorder
- Nightmare
- Mental disorder due to a general medical condition
- Palpitations
- Pathological gambling
- Pericardial effusion
- Pericarditis
- Pleural effusion
- Pleurisy
- Pulmonary fibrosis
- Retroperitoneal fibrosis
- Hyperhidrosis
- Tachycardia
- Angiopathy
- Vertigo
- Vomiting
- Weight increased
- Weight decreased
- Dry mouth
- Oedema peripheral
- Malnutrition
- Constipation
- Abdominal discomfort
- Disorientation
- Aggression
- Peripheral coldness
- Hypersexuality
- Blood pressure increased
- Dementia
- Binge eating
- Syncope
- Insomnia
- Sudden onset of sleep
- Regurgitation
- Pleural fibrosis
- Somnolence
Indications
- Acromegaly
- Akinesia
- Amenorrhoea
- Bradykinesia
- Dyskinesia
- Galactorrhoea
- Growth hormone overproduction
- Hypokinesia
- Increased prolactin level
- Infertility
- Nausea
- Neoplasm
- Parkinson's disease
- Parkinsonism
- Parkinsonism post encephalitic
- Pituitary tumour
- Prolactinoma
- Rigors
- Tremor
Legal status []
- Brazil: Lisuride is a C1.[3]
- Other: Lisuride is a Rx-only.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 28864, Lisuride. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/28864
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Lisuride. UNII: E0QN3D755O. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/E0QN3D755O
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 03:05:44 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 03:05:40 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 03:05:40 |
| gsrs | ok | 2026-11-20 03:05:41 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014727) | 2026-11-20 03:05:40 |
| kegg | ok | 2026-11-20 03:05:42 |
| pubchem | ok | 2026-11-20 03:05:40 |
| missing (no r/tripreports posts mention it) | 2026-11-20 03:05:40 | |
| sider | ok | 2026-11-20 03:05:40 |
| structure | ok | 2026-11-20 03:05:40 |
| wikipedia | ok | 2026-11-20 03:05:41 |